ARTA
AIMT

A.R.T. Advisors’s Aimmune Therapeutics AIMT Stock Holding History

A.R.T. Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-43,836
Closed -$918K – 1890
2019
Q3 		$918K Buy
+43,836
New +$895K 0.05% 591
2019
Q1 		– Sell
-37,734
Closed -$903K – 1762
2018
Q4 		$903K Buy
37,734
+29,100
+337% +$753K 0.06% 475
2018
Q3 		$235K Sell
8,634
-19,200
-69% -$543K 0.01% 1135
2018
Q2 		$748K Buy
+27,834
New +$852K 0.03% 762
2018
Q1 		– Sell
-5,440
Closed -$205K – 1871
2017
Q4 		$205K Buy
+5,440
New +$176K 0.01% 1154

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

A.R.T. Advisors's AIMT Position: Q4 2019 in Review

A.R.T. Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 43,836 shares — an estimated $918K sold.

A.R.T. Advisors first reported a position in AIMT in Q4 2017 and held it in 5 quarters. The position peaked at $918K in Q3 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • A.R.T. Advisors reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 43,836 Aimmune Therapeutics shares in Q4 2019, an estimated $918K.
  • A.R.T. Advisors first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 5 quarters.
  • A.R.T. Advisors's Aimmune Therapeutics position peaked at $918K in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.